{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:21:50Z","timestamp":1785529310651,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02838-4","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:50:11Z","timestamp":1694699411000},"page":"4279-4287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anterior segment complications after dexamethasone implantations:real world data"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-8534","authenticated-orcid":false,"given":"Yusuf","family":"Ayaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-6618","authenticated-orcid":false,"given":"\u00c7isil","family":"Erkan Pota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6409-8751","authenticated-orcid":false,"given":"\u0130brahim","family":"Ba\u015fol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-4861","authenticated-orcid":false,"given":"Mehmet Erkan","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-591X","authenticated-orcid":false,"given":"Elif Bet\u00fcl","family":"T\u00fcrko\u011flu \u015een","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-6390","authenticated-orcid":false,"given":"Mustafa","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"2838_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0896-1549(02)00043-3","volume":"15","author":"C Pelzek","year":"2002","unstructured":"Pelzek C, Lim JI (2002) Diabetic macular edema: review and update. Ophthalmol Clin North Am 15:555\u2013563","journal-title":"Ophthalmol Clin North Am"},{"issue":"Suppl 1","key":"2838_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000315155","volume":"224","author":"S Scholl","year":"2010","unstructured":"Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 224(Suppl 1):8\u201315","journal-title":"Ophthalmologica"},{"key":"2838_CR3","first-page":"1153","volume":"130","author":"SB Bressler","year":"2012","unstructured":"Bressler SB, Qin H, Beck RW et al (2012) Diabetic retinopathy clinical research network. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. ArchOphthalmol 130:1153\u20131161","journal-title":"ArchOphthalmol"},{"issue":"6","key":"2838_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: 6-month primary end point results of a phase III study. Ophthalmology 117(6):1124\u20131133. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.022","journal-title":"Ophthalmology"},{"issue":"11","key":"2838_CR5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","volume":"137","author":"P Hykin","year":"2019","unstructured":"Hykin P, Prevost AT, Vasconcelos JC et al (2019) Clinical effectiveness of intravitreal therapy with ranibizumab versus aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol 137(11):1256\u20131264. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.3305","journal-title":"JAMA Ophthalmol"},{"key":"2838_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40942-018-0114-2","volume":"4","author":"SK Mishra","year":"2018","unstructured":"Mishra SK, Gupta A, Patyal S et al (2018) Intravitreal dexamethasone implant versus triamcinolone acetonide for macular edema of central retinal vein occlusion: quantifying efficacy and safety. Int J Retin Vitr 4:13. https:\/\/doi.org\/10.1186\/s40942-018-0114-2","journal-title":"Int J Retin Vitr"},{"key":"2838_CR7","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort RJ et al (2014) Ozurdex MEAD studygroup. Three-year, randomized, sham-controlled trial dexamethasone intravitreal implants in patients with diabetic macular edema. Ophthalmology 121:1904\u20131914","journal-title":"Ophthalmology"},{"issue":"11","key":"2838_CR8","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00417-018-4095-5","volume":"256","author":"J Blanc","year":"2018","unstructured":"Blanc J, Kodjikian L, Bron A, Creuzot-Garcher C (2018) Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. Graefe\u2019s Arch Clin Exp Ophthalmol 256(11):2271\u20132271","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2838_CR9","first-page":"560","volume":"29","author":"LM Meyer","year":"2013","unstructured":"Meyer LM, Sch\u00f6nfeld C-L (2013) Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a 1-year follow-up. J OculPharmacolTher 29:560\u2013565","journal-title":"J OculPharmacolTher"},{"key":"2838_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00347-012-2737-2","volume":"111","author":"K Schmitz","year":"2014","unstructured":"Schmitz K, Maier M, Clemens CR et al (2014) Reliability and safety of intravitreal Ozurdex injections. The ZERO study. Ophthalmologe 111:44\u201352","journal-title":"Ophthalmologe"},{"key":"2838_CR11","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N et al (2017) Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 37:1352\u20131359","journal-title":"Retina"},{"key":"2838_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000337144","volume":"3","author":"A Russo","year":"2012","unstructured":"Russo A, Avitabile T, Uva M et al (2012) Radiation macular edema after Ru-106 plaque brachytherapy for choroidal melanoma resolved by an intravitreal dexamethasone 0.7-mg implant. Case RepOphthalmol 3:71\u201376","journal-title":"Case RepOphthalmol"},{"key":"2838_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000332424","volume":"2","author":"LM Meyer","year":"2011","unstructured":"Meyer LM, Sch\u00f6nfeld C-L (2011) Cystoid macular edema after complicated cataract surgery resolved by an intravitreal dexamethasone 0.7-mg implant. Case RepOphthalmol 2:319\u2013322","journal-title":"Case RepOphthalmol"},{"key":"2838_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000448057","volume":"236","author":"A Klamann","year":"2016","unstructured":"Klamann A, B\u00f6ttcher K, Ackermann P et al (2016) Intravitreal dexamethasone implant for the treatment of postoperative macular edema. Ophthalmologica 236:181\u2013185","journal-title":"Ophthalmologica"},{"key":"2838_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jcjo.2015.01.007","volume":"50","author":"S Lei","year":"2015","unstructured":"Lei S, Lam W-C (2015) Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. Can J Ophthalmol 50:236\u2013241","journal-title":"Can J Ophthalmol"},{"key":"2838_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000492132","volume":"241","author":"P MelloFilho","year":"2019","unstructured":"MelloFilho P, Andrade G, Maia A et al (2019) Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: a real World experience. Ophthalmologica 241:9\u201316","journal-title":"Ophthalmologica"},{"issue":"1","key":"2838_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12886-018-0779-1","volume":"18","author":"Y He","year":"2018","unstructured":"He Y, Ren XJ, Hu BJ, Lam WCLX (2018) A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic maculare dema. BMC Ophthalmol 18(1):121","journal-title":"BMC Ophthalmol"},{"key":"2838_CR18","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal veinocclusion 12-month study results. Ophthalmology 118:2453\u20132460","journal-title":"Ophthalmology"},{"key":"2838_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00417-017-3831-6","volume":"256","author":"X Li","year":"2018","unstructured":"Li X, Wang N, Liang X (2018) Safetyandefficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256:59\u201369","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2838_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00417-016-3431-x","volume":"255","author":"N Eter","year":"2017","unstructured":"Eter N, Mohr A, Wachtlin J (2017) Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255:77\u201387","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2838_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/tjo.tjo_62_17","volume":"8","author":"M Nagpal","year":"2018","unstructured":"Nagpal M, Mehrotra N, Juneja R et al (2018) Dexamethasone implant (0.7 mg) in Indianpatients with macular edema: real-life scenario. Taiwan J Ophthalmol 8:141\u2013148","journal-title":"Taiwan J Ophthalmol"},{"key":"2838_CR22","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.ajo.2014.09.003","volume":"158","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Carre\u00f1o E, Johnston RL et al (2014) Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, andreinjectionfrequency. Am J Ophthalmol 158:1136\u20131145","journal-title":"Am J Ophthalmol"},{"key":"2838_CR23","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/eye.2013.79","volume":"27","author":"WJ Mayer","year":"2013","unstructured":"Mayer WJ, Wolf A, Kernt M et al (2013) Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye 27:816\u2013822","journal-title":"Eye"},{"issue":"1","key":"2838_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/iae.0000000000001924","volume":"39","author":"Srinivasan Rekha, Sharma Unnati, George Ronnie, Raman Rajiv, Sharma Tarun, Sankara Nethralaya Vitreoretinal Study Group","year":"2019","unstructured":"Srinivasan Rekha, Sharma Unnati, George Ronnie, Raman Rajiv, Sharma Tarun, Sankara Nethralaya Vitreoretinal Study Group (2019) Intraocular pressure changes after dexamethasone implant in patients with glaucoma and steroid responders. Retina 39(1):157\u2013162. https:\/\/doi.org\/10.1097\/iae.0000000000001924","journal-title":"Retina"},{"issue":"12","key":"2838_CR25","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","volume":"121","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Lim LL, Campain A et al (2014) randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macularedema: the BEVORDEX study. Ophthalmology. 121(12):2473\u20132481. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.002","journal-title":"Ophthalmology."},{"issue":"27","key":"2838_CR26","doi-asserted-by":"publisher","first-page":"e29807","DOI":"10.1097\/MD.0000000000029807","volume":"101","author":"P Jirarattanasopa","year":"2022","unstructured":"Jirarattanasopa P, Jiranoppasakdawong S, Ratanasukon M, Bhurayanontachai P, Dangboon W (2022) Results of intravitreal dexamethasone implant (Ozurdex\u00ae) for retinal vascular diseases with macular edema: an observational study of real-life situations. Medicine (Baltimore) 101(27):e29807. https:\/\/doi.org\/10.1097\/MD.0000000000029807","journal-title":"Medicine (Baltimore)"},{"key":"2838_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","volume":"127","author":"IU Scott","year":"2009","unstructured":"Scott IU, Ip MS, VanVeldhuisen PC et al (2009) SCORE study research group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the standard care versus corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol 127:1115\u20131122","journal-title":"Arch Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02838-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T11:12:37Z","timestamp":1695640357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02838-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2838"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02838-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"2 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no confict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Akdeniz University Medical Faculty. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent to participate and publish Informed consent for publication of their clinical details and\/or clinical images was obtained from all individual participants included in the study. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}